Dr. Reddy's Laboratories Expects the Launch of Versavo (biosimilar, bevacizumab) for the Treatment of Several Cancer Indications Across the UK
Shots:
- The company has developed Versavo as a biosimilar of Avastin, approved for the treatment of various cancer indications incl. metastatic colorectal cancer, advanced non-squamous NSCLC, recurrent glioblastoma, mRCC, advanced cervical cancer, ovarian cancer & metastatic breast cancer
- Based on the clinical evaluation, Versavo is expected to be approved and launched across the UK as a single-use vial in strengths 100 & 400mg
- Earlier in 2019, Dr. Reddy’s launched Versavo in India and has also launched the Avastin biosimilar in markets across Thailand, Ukraine, Nepal & Jamaica under the same brand name & in Colombia by Persivia
Ref: Dr. Reddy's | Image: Dr. Reddy's
Related News:- Dr. Reddy’s Reports BLA Acceptance for DRL_RI, a Proposed Biosimilar Rituximab by the US FDA, EMA and MHRA
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
